Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ATYR Stock Forecast 2026-2027
$0.85
Current Price
$83.29M
Market Cap
Buy 3
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to ATYR Price Targets
+2,252.9%
To High Target of $20.00
+17.6%
To Median Target of $1.00
+17.6%
To Low Target of $1.00
ATYR Price Momentum
+3.7%
1 Week Change
-4.5%
1 Month Change
-78.6%
1 Year Change
+9.0%
Year-to-Date Change
-88.3%
From 52W High of $7.29
+32.8%
From 52W Low of $0.64
📊 TOP ANALYST CALLS
Did ATYR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if aTyr Pharma is one of their latest high-conviction picks.
Latest ATYR Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, ATYR has a neutral consensus with a median price target of $1.00 (ranging from $1.00 to $20.00). The overall analyst rating is Buy (6.8/10). Currently trading at $0.85, the median forecast implies a 17.6% upside. This outlook is supported by 3 Buy, 7 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Brian Abrahams at RBC Capital, suggesting a 17.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ATYR Analyst Ratings
3
Buy
7
Hold
0
Sell
ATYR Price Target Range
Low
$1.00
Average
$1.00
High
$20.00
Current: $0.85
Latest ATYR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ATYR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 7, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $1.00 |
| Sep 16, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Downgrade | $1.50 |
| Sep 16, 2025 | Wells Fargo | Derek Archila | Equal-Weight | Downgrade | $1.00 |
| Sep 15, 2025 | LUCID CAPITAL MARKETS | Neutral | Downgrade | $N/A | |
| Sep 15, 2025 | HC Wainwright & Co. | Joseph Pantginis | Neutral | Downgrade | $N/A |
| Sep 15, 2025 | Cantor Fitzgerald | Neutral | Downgrade | $N/A | |
| Sep 15, 2025 | Leerink Partners | Market Perform | Downgrade | $N/A | |
| Sep 15, 2025 | Jones Trading | Hold | Downgrade | $N/A | |
| Aug 22, 2025 | Jefferies | Roger Song | Buy | Maintains | $17.00 |
| Jun 20, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $25.00 |
| Jun 4, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| May 19, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Feb 18, 2025 | Leerink Partners | Faisal Khurshid | Outperform | Initiates | $16.00 |
| Jan 6, 2025 | Cantor Fitzgerald | Prakhar Agrawal | Overweight | Initiates | $N/A |
| Dec 10, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Dec 3, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Oct 29, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Oct 4, 2024 | Wells Fargo | Derek Archila | Overweight | Initiates | $17.00 |
| Sep 5, 2024 | Jefferies | Roger Song | Buy | Initiates | $9.00 |
Atyr Pharma Inc. (ATYR) Competitors
The following stocks are similar to aTyr Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ATYR
aTyr Pharma
mkt cap
83.29M
Atyr Pharma Inc. (ATYR) Financial Data
Atyr Pharma Inc. has a market capitalization of $83.29M with a P/E ratio of -1.0x. The company generates $190,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -40,856.3% and return on equity of -108.1%.
Valuation Metrics
Market Cap
$83.29M
Enterprise Value
$18.21M
P/E Ratio
-1.0x
PEG Ratio
-0.1x
Price/Sales
429.4x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-40,856.3%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+94.5%
Current Ratio
5.3x
Debt/Equity
17.9x
ROE
-108.1%
ROA
-51.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Atyr Pharma Inc. (ATYR) Business Model
About Atyr Pharma Inc.
What They Do
Develops therapeutics using innovative biological pathways.
Business Model
Atyr Pharma Inc. generates revenue by developing novel therapeutics that target unmet medical needs, particularly in fibrotic lung diseases, cancer, and inflammation-related disorders. The company focuses on translating their research on extracellular proteins, specifically tRNA synthetases, into clinically viable treatments, engaging in partnerships with academic and industry collaborators to bring these innovations to market.
Additional Information
Headquartered in San Diego, California, Atyr Pharma operates in the competitive biotechnology sector, contributing to significant advancements in medical research and development. Their lead clinical program addresses interstitial lung diseases, an area with substantial opportunities for therapeutic improvement.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
58
CEO
Dr. Sanjay S. Shukla M.D., M.S.
Country
United States
IPO Year
2015
Website
atyrpharma.comAtyr Pharma Inc. (ATYR) Latest News & Analysis
Latest News
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
9 days ago
Quick Summary
The company will meet with the FDA in April 2026 to discuss Phase 3 results of efzofitimod for pulmonary sarcoidosis and expects Phase 2 enrollment for SSc-ILD to finish by mid-2026.
Why It Matters
The FDA meeting in April 2026 could influence efzofitimod's approval timeline, impacting the company's stock value and investor sentiment based on study outcomes.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
aTyr Pharma granted two employees stock options for 12,200 shares at an exercise price of $0.98, aligning with the stock's closing price on February 17, 2026, under its 2022 Inducement Plan.
Why It Matters
The grant of stock options to new employees indicates aTyr Pharma's commitment to attracting talent, potentially driving innovation and growth, which can positively influence stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
aTyr Pharma, Inc. (Nasdaq: ATYR) announced Dr. Sanjay S. Shukla as part of its leadership team, focusing on developing first-in-class medicines from its tRNA synthetase platform.
Why It Matters
Leadership changes at aTyr Pharma could impact strategic direction and investor confidence, affecting stock performance and future funding opportunities in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
aTyr Pharma's FDA meeting to discuss efzofitimod for pulmonary sarcoidosis is set for mid-April 2026, following the Phase 3 EFZO-FIT™ study results.
Why It Matters
The FDA meeting indicates potential regulatory progress for efzofitimod, impacting aTyr Pharma's valuation and prospects in the competitive biotech market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Forgent Power Solutions, Liftoff Mobile, and multiple consumer and biotech companies are preparing to launch initial public offerings (IPOs).
Why It Matters
The IPOs of Forgent Power Solutions, Liftoff Mobile, and other firms could create investment opportunities and influence market sentiment, impacting stock valuations and sector performance.
Source: Barrons
Market Sentiment:
Neutral
Ethos Technologies: A Surprisingly Soft Debut
1 month ago
Quick Summary
Ethos Technologies experienced a weaker-than-expected market debut, indicating potential challenges ahead for the company's stock performance.
Why It Matters
Ethos Technologies' weak market debut may signal concerns about its growth potential and investor confidence, impacting stock valuations and market sentiment in the tech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About ATYR Stock
What is Atyr Pharma Inc.'s (ATYR) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Atyr Pharma Inc. (ATYR) has a median price target of $1.00. The highest price target is $20.00 and the lowest is $1.00.
Is ATYR stock a good investment in 2026?
According to current analyst ratings, ATYR has 3 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ATYR stock?
Wall Street analysts predict ATYR stock could reach $1.00 in the next 12 months. This represents a 17.6% increase from the current price of $0.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Atyr Pharma Inc.'s business model?
Atyr Pharma Inc. generates revenue by developing novel therapeutics that target unmet medical needs, particularly in fibrotic lung diseases, cancer, and inflammation-related disorders. The company focuses on translating their research on extracellular proteins, specifically tRNA synthetases, into clinically viable treatments, engaging in partnerships with academic and industry collaborators to bring these innovations to market.
What is the highest forecasted price for ATYR Atyr Pharma Inc.?
The highest price target for ATYR is $20.00 from at , which represents a 2,252.9% increase from the current price of $0.85.
What is the lowest forecasted price for ATYR Atyr Pharma Inc.?
The lowest price target for ATYR is $1.00 from Brian Abrahams at RBC Capital, which represents a 17.6% increase from the current price of $0.85.
What is the overall ATYR consensus from analysts for Atyr Pharma Inc.?
The overall analyst consensus for ATYR is neutral. Out of 8 Wall Street analysts, 3 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $1.00.
How accurate are ATYR stock price projections?
Stock price projections, including those for Atyr Pharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 10:23 AM UTC